company background image
SIEN

Sientra NasdaqGS:SIEN Stock Report

Last Price

US$1.17

Market Cap

US$73.3m

7D

-9.3%

1Y

-82.9%

Updated

16 May, 2022

Data

Company Financials +
SIEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

SIEN Stock Overview

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally.

Sientra Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sientra
Historical stock prices
Current Share PriceUS$1.17
52 Week HighUS$9.14
52 Week LowUS$1.15
Beta2.11
1 Month Change-41.21%
3 Month Change-64.00%
1 Year Change-82.93%
3 Year Change-83.52%
5 Year Change-84.44%
Change since IPO-93.39%

Recent News & Updates

Shareholder Returns

SIENUS Medical EquipmentUS Market
7D-9.3%3.0%0.7%
1Y-82.9%-15.1%-10.8%

Return vs Industry: SIEN underperformed the US Medical Equipment industry which returned -15.6% over the past year.

Return vs Market: SIEN underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is SIEN's price volatile compared to industry and market?
SIEN volatility
SIEN Average Weekly Movement12.2%
Medical Equipment Industry Average Movement10.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: SIEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: SIEN's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003319Ron Menezeshttps://sientra.com

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers.

Sientra Fundamentals Summary

How do Sientra's earnings and revenue compare to its market cap?
SIEN fundamental statistics
Market CapUS$73.29m
Earnings (TTM)-US$23.89m
Revenue (TTM)US$83.77m

0.9x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SIEN income statement (TTM)
RevenueUS$83.77m
Cost of RevenueUS$36.74m
Gross ProfitUS$47.03m
Other ExpensesUS$70.92m
Earnings-US$23.89m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin56.14%
Net Profit Margin-28.52%
Debt/Equity Ratio282.0%

How did SIEN perform over the long term?

See historical performance and comparison

Valuation

Is Sientra undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.92x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SIEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SIEN's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: SIEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SIEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SIEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SIEN is overvalued based on its PB Ratio (2.9x) compared to the US Medical Equipment industry average (2.5x).


Future Growth

How is Sientra forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-2.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIEN's revenue (15.8% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: SIEN's revenue (15.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SIEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sientra performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SIEN is currently unprofitable.

Growing Profit Margin: SIEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SIEN is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.

Accelerating Growth: Unable to compare SIEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).


Return on Equity

High ROE: SIEN has a negative Return on Equity (-95.24%), as it is currently unprofitable.


Financial Health

How is Sientra's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SIEN's short term assets ($134.9M) exceed its short term liabilities ($84.7M).

Long Term Liabilities: SIEN's short term assets ($134.9M) exceed its long term liabilities ($82.1M).


Debt to Equity History and Analysis

Debt Level: SIEN's net debt to equity ratio (127%) is considered high.

Reducing Debt: SIEN's debt to equity ratio has increased from 0.07% to 282% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIEN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SIEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.5% each year


Dividend

What is Sientra current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SIEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SIEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SIEN has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Ron Menezes (59 yo)

1.5yrs

Tenure

US$1,100,000

Compensation

Mr. Ronald Menezes, also known as Ron, has been President and Chief Executive Officer of Sientra, Inc. since November 10, 2020 and serves as its Director. Mr. Menezes served as President and General Manage...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD1.10M) is above average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SIEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: SIEN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.


Top Shareholders

Company Information

Sientra, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sientra, Inc.
  • Ticker: SIEN
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$73.289m
  • Shares outstanding: 62.64m
  • Website: https://sientra.com

Number of Employees


Location

  • Sientra, Inc.
  • 420 South Fairview Avenue
  • Suite 200
  • Santa Barbara
  • California
  • 93117
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.